Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Research and development - MRTP

Sales, general and administrative

Impairment of intangible assets

Depreciation

Amortization

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

22nd Century Group

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

22nd Century Group advances VLN and GVB units towards profitability

22nd Century Group's Q4 2022 earnings call highlighted progress in VLN tobacco and GVB hemp/cannabis units, with plans for multi-state launches and cash positive operations in 2024. Despite challenges like the Grass Valley facility fire, the company remains focused on achieving profitability through revenue growth and market expansion. Key strengths include successful pilot results, volume growth, and a clear path to cash positivity for both business units.

22nd Century Group (XXII) reports strong Q1 performance and growth strategies

22nd Century Group (XXII) showcases strong performance and strategic initiatives to drive revenue growth and achieve cash positivity by 2024.
Despite challenges such as analyst inquiries and insurance impacts, the company's focus on cost efficiencies and margin improvements positions it for success.
Opportunities in revenue growth, bulk ingredient capacity expansion, and margin enhancements present promising prospects for future profitability and market growth.

22nd Century Group reports strong Q2 performance amidst operational challenges

22nd Century Group's Q2 performance showcased growth in sales but faced challenges in gross profit due to production mix shifts.
The company's proactive strategies for cost savings, brand value creation, and gross margin improvement indicate a focus on long-term sustainability.
Despite challenges like VLN rollout delays and tobacco business hurdles, opportunities in market differentiation and efficiency improvements are being pursued.

22nd Century Group pursues profitability through strategic shifts and cost management

22nd Century Group's Q4 2023 earnings call highlighted efforts to achieve profitability by reducing cash burn, focusing on VLN cigarettes for harm reduction, and exploring CMO opportunities in tobacco manufacturing. Despite challenges like decreased net sales and a negative gross profit, the company aims to reach breakeven by Q1 2025.

22nd Century Group reduces cash burn, aims for profitability by 2025

22nd Century Group's Q1 2024 performance reflects progress towards profitability, with improved financial discipline and operational efficiency.
While facing revenue challenges and legal disputes, the company's strategic initiatives and investor support position it for future growth and success.
The focus on reducing losses, strengthening the balance sheet, and expanding market presence underscores the company's commitment to long-term sustainability.

22nd Century Group reports Q2 financial turnaround and growth strategies

22nd Century Group's Q2 2024 performance reflects a notable financial turnaround and progress towards profitability.
Strategic initiatives, leadership appointments, and product strategies position the company for future growth and success.
While challenges remain in achieving cash positive operations, opportunities in market expansion and product innovation offer avenues for continued advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

New intellectual property facilitates the precise control and modulation of cannabinoid production New intellectual property facilitates the precise control and modulation of cannabinoid production

22nd Century Group Achieves Breakthrough Hemp/Cannabis GMO Technology; Granted New Patent for Controlling Genes Responsible for Production of CBD, THC, and Other Valuable Cannabinoids

Investors need to pay close attention to 22nd Century (XXII) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in 22nd Century (XXII) Stock?

There are reasons to believe that the company will receive MRTP status, which enables the company to be the only company to sell and market VLN cigarettes. While investors have already piled in, MRTP status is a company-changing event, and the odds look pretty good.

22nd Century Looks Set To Finally Cash In

The Company's Research Cigarettes Continue to Fuel Studies Adding to the Vast Body of Research Supporting a National Nicotine Standard for Combustible Cigarettes The Company's Research Cigarettes Continue to Fuel Studies Adding to the Vast Body of Research Supporting a National Nicotine Standard for Combustible Cigarettes

22nd Century Receives Order for 3.6 Million New SPECTRUM® Variable Nicotine Cigarettes for U.S. Government-Supported Research

WILLIAMSVILLE, N.Y., Nov. 18, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII ), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that Chief Executive Officer, James A. Mish, will speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 11:50 a.m. EST. The virtual conference is a forum for objective first-hand updates on both marketed and emerging products across the spectrum of the cannabis industry focusing on consumer, technology, and healthcare.

22nd Century Group CEO James A. Mish to Speak at Cowen 2020 Boston Cannabis Conference

WILLIAMSVILLE, N.Y., Nov. 16, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that the Company will present and meet with investors at the Virtual Fall Investor Summit. The conference is being held virtually November 16 -18, 2020.

22nd Century Group to Present at the Virtual Fall Investor Summit on November 17

22nd Century Group, Inc. (XXII) CEO James Mish on Q3 2020 Results - Earnings Call Transcript

22nd Century (XXII) delivered earnings and revenue surprises of 25.00% and 32.91%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

22nd Century Group (XXII) Reports Q3 Loss, Tops Revenue Estimates

22nd Century Group Reports Financial Results and Business Highlights for the Third Quarter 2020

22nd Century (XXII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

22nd Century Group (XXII) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

WILLIAMSVILLE, N.Y., Oct. 22, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, life science company driven by next generation biotechnology, will host a live audio webcast on Thursday, November 5, 2020 at 8:00 a.m. Eastern Standard Time to discuss its 2020 third quarter results. 22nd Century will report the Company's third quarter 2020 results in a press release at 7:00 a.m. Eastern Standard Time the same day.

22nd Century Group to Host Third Quarter 2020 Webcast and Conduct Quarterly Q&A

The U.S. Food and Drug Administration to provide an update on the Agency's Comprehensive Plan for Tobacco and Nicotine Regulation The U.S. Food and Drug Administration to provide an update on the Agency's Comprehensive Plan for Tobacco and Nicotine Regulation

22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute's Tobacco and Nicotine Products Regulation and Policy Conference

22nd Century (XXII) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

22nd Century (XXII) in Focus: Stock Moves 9.9% Higher

New intellectual property leads to precise genetic control over nicotine levels in virtually any variety of the tobacco plant New intellectual property leads to precise genetic control over nicotine levels in virtually any variety of the tobacco plant

22nd Century Group Achieves Breakthrough Technology; Granted New Patent for Reducing Nicotine in Tobacco Plants

WILLIAMSVILLE, N.Y., Sept.  24, 2020  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant-based, life science company driven by next generation biotechnology, today provided a strategy update letter from Chief Executive Officer, James A. Mish.

22nd Century Group Provides Strategy Update Letter from CEO

WILLIAMSVILLE, N.Y., Aug.  27, 2020  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant-based life science company driven by next generation plant biotechnology, today announced that the Company’s executive management team will present at the LD Micro 500 Virtual Conference on Thursday, September 3, 2020 at 4:20 p.m. ET and will be available for one-on-one meetings with investors throughout the day on September 3 and 4, 2020.

22nd Century Group to Present at the LD Micro 500 Virtual Conference

22nd Century Group, Inc. (XXII) CEO Jim Mish on Q2 2020 Results - Earnings Call Transcript

22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020

22nd Century Group, Inc. Common Stock Inc (AMEX:XXII) was trading 2.4% higher from the previous closing price.

Insider Buys 22nd Century Group's Stock

Mish brings extensive global executive leadership experience in the development, manufacturing and commercialization of active pharmaceutical ingredients, including cannabinoids, and related consumer products

22nd Century Group Appoints James A. Mish as Chief Executive Officer and John Franzino as Chief Financial Officer

22nd Century Group, Inc. (XXII) Q1 2020 Results - Earnings Call Transcript

22nd Century Group achieves another important milestone in the FDA’s scientific review of the Company’s MRTP application for its reduced nicotine content cigarettes 22nd Century Group achieves another important milestone in the FDA’s scientific review of the Company’s MRTP application for its reduced nicotine content cigarettes

FDA Announces Deadline to Submit Comments on 22nd Century Group’s MRTP Application

Williamsville, NY, April  08, 2020  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, announced today that the Company will hold its 2020 Annual Meeting of Stockholders using a virtual meeting format.  The decision to move to a virtual meeting was done in order to protect the health and safety of meeting participants during the coronavirus (COVID-19) pandemic. 

22nd Century Group to Hold Virtual Annual Meeting of Stockholders

Delivers Complete High-Quality Hemp/Cannabis Genome Sequence; Establishes New Proprietary Hemp/Cannabis Bioinformatics Platform

22nd Century Announces Important New Achievements with KeyGene

New Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Efforts and Improve Investor Engagement New Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Efforts and Improve Investor Engagement

News for 22nd Century Group Stock (XXII)